Penpulimab is approved for multiple indications in China, but this marks the first US approval for the novel monoclonal ...

Penpulimab-kcqx, a humanized immunoglobulin G1 monoclonal antibody, blocks the interaction between the programmed death 1 receptor on T-cells and programmed death ligand 1 and 2 on tumor cells.

The antibody is to treat adult recurrent or metastatic non-keratinising nasopharyngeal carcinoma (NPC) in conjunction with ...

Compromised antigen presentation ranks among the top mechanisms that render cancers non-immunogenic (non-responsive to immune ...